Bayer Logo Bayer Logo Bayer Logo

Phase II ARTS Programme

Preliminary efficacy
and safety

Phase II ARTS programme

The phase II ARTS programme investigated the efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes/heart failure. Reductions in albuminuria were observed with a similar safety profile to placebo.4-6

Alt tag

Overview of the studies and findings from the ARTS programme4-6 

© 2020 Bayer AG

This website is intended to provide information to an international audience outside the USA and UK

Last update: 18/09/2020